LSE creators

Number of items: 20.
Health Policy
  • McIntyre, Finlay, Lin, Ryan, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA155 From license to reimbursement: a slot-based ML framework for seamless MA to HTA alignment. Value in Health, 28(12, Supplement 1), S433 - S434. https://doi.org/10.1016/j.jval.2025.09.1940
  • Eaves, Kristian, Mills, Mackenzie, Kanavos, Panos, Tolkmitt, Fiona, Alani, Ahmad Hecham (2025). HTA225 LLM engineering in HEOR: approaches to improving accuracy in clinical data extraction. Value in Health, 28(12, Supplement 1), S448 - S449. https://doi.org/10.1016/j.jval.2025.09.2009
  • Alani, Ahmad Hecham, Sharma, Abhinaw, Chellani, Lehar, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA27 Advocating from the margins: how patient input aligns with broader evidence tolerance in HTA within oncology. Value in Health, 28(12, Supplement 1), S405. https://doi.org/10.1016/j.jval.2025.09.1812
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA54 Beyond RCTs the role of patient perspectives and nontraditional evidence in HTA decisions for breast cancer (BC) and non-small cell lung cancer (NSCLC). Value in Health, 28(12, Supplement 1), S411. https://doi.org/10.1016/j.jval.2025.09.1839
  • Federico, Augustovski, Chávez, Danitza, Haig, Madeleine, Main, Caitlin, Argento, Fernando, Colaci, Carla, Mills, Mackenzie, Alfie, Verónica, Pichon Riviere, Andrés & Alcaraz, Andrea et al (2025). A Delphi study on valuing DNA sequencing in oncology: a European stakeholder developed framework for assessing next generation sequencing and comprehensive genomic profiling diagnostics. EBioMedicine, 121, https://doi.org/10.1016/j.ebiom.2025.105947 picture_as_pdf
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanya, Lucy, Kanavos, Panos, Al-Omar, Hussain A. (2025). HTA23 Broadening the evidence base: incorporating environmental considerations Into HTAs. Value in Health, 28(6, Supplement 1), S251. https://doi.org/10.1016/j.jval.2025.04.1034
  • Alani, Ahmad Hecham, Mills, Mackenzie, Kanavos, Panos (2025). HTA43 Assessing the added value of fixed-dose combinations in non-communicable diseases a comparative HTA analysis across Canada, Scotland, France, and Germany (2014-2024). Value in Health, 28(6, Supplement 1), S254. https://doi.org/10.1016/j.jval.2025.04.1054
  • Civitelli, Diego, Mills, Mackenzie, Kanavos, Panos (2025). HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28(6, Supplement 1), S259. https://doi.org/10.1016/j.jval.2025.04.1080
  • Bergsteedt, Matthew, Tolkmitt, Fiona, Mills, Mackenzie, Kanavos, Panos (2025). HTA92 Diffusion and launch sequencing of cell and gene therapies across the USA, Europe, Canada and Australia. Value in Health, 28(6, Supplement 1), S263 - S264. https://doi.org/10.1016/j.jval.2025.04.1103
  • Eaves, Kristian, Zaitceva, Viktoriia, Lin, Ryan, Mills, Mackenzie, Kanavos, Panos (2025). MSR17 A comparative assessment of LLM agreement for clinical data extraction tasks. Value in Health, 28(6, Supplement 1), S277. https://doi.org/10.1016/j.jval.2025.04.1170
  • Zaitceva, Viktoriia, Eaves, Kristian, Mills, Mackenzie, Kanavos, Panos (2025). P53 Alignment between CDA recommendations and pCPA negotiation outcomes: exploring factors influencing reimbursement success. Value in Health, 28(6, Supplement 1), S19. https://doi.org/10.1016/j.jval.2025.04.071
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843
  • Alani, A. H., Eaves, K., Mills, Mackenzie, Kanavos, P. (2024). HTA246 Improving access to innovative therapies for rare bleeding disorders: evidence from high income countries. Value in Health, 27(12), S402 - S403. https://doi.org/10.1016/j.jval.2024.10.2071
  • Tolkmitt, F., Chavez, D., Mills, M., Kanavos, P. (2024). HTA354 Determinants of added benefit ratings in Germany: an econometric analysis of assessments from the Federal Joint Committee between 2012 and 2024. Value in Health, 27(12 Supplement), S425 - S425. https://doi.org/10.1016/j.jval.2024.10.2179
  • Candore, Gianmario, Martin, Claire, Gabarro, Montse Soriano, Mills, Mackenzie, Kanavos, Panos, Bromley, Susan, Cooper, Amy L., Wolf, Birgit, Bolot, Paul & Franklin, Joe et al (2024). Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs: evidence from North America, Europe, and Australia. Pharmacoepidemiology and Drug Safety, 33, 542 - 543. https://doi.org/10.1002/pds.5891
  • Augustovski, Federico, Colaci, Carla, Mills, Mackenzie, Chávez, Danitza, Argento, Fernando, Alfie, Verónica, Pichon Riviere, Andrés, Kanavos, Panos, Alcaraz, Andrea (2024). A systematic review of value criteria for next-generation sequencing/ comprehensive genomic profiling to inform value framework development. Value in Health, 27(5), 670 - 685. https://doi.org/10.1016/j.jval.2024.02.002 picture_as_pdf
  • Kanavos, Panos, Alcaraz, OA, Chávez, Danitza, Colaci, C, Haig, Madeleine, Argento, F, Main, Caitlin, Alfie, Verónica, Mills, Mackenzie & Pichon-Riviere, DA et al (2023). HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe: building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Value in Health, 26(12), S355 - S355. https://doi.org/10.1016/j.jval.2023.09.1870
  • Politopoulou, Konstantina, Mills, Mackenzie, Kanavos, Panos (2023). HTA255 First-in-class drugs in HTA blunder or bliss? Value in Health, 26(12), S369 - S369. https://doi.org/10.1016/j.jval.2023.09.1938
  • Mills, Mackenzie John (2023). Regulatory policies vs HTA practices and their impact on access to innovative treatments [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.00004696
    • LSE
  • Candore, Gianmario, Martin, Claire, Gabarro, Montse Soriano, Mills, Mackenzie, Kanavos, Panos, Bromley, Susan, Cooper, Amy L., Wolf, Birgit, Bolot, Paul & Franklin, Joe et al (2024). Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs: evidence from North America, Europe, and Australia. Pharmacoepidemiology and Drug Safety, 33, 542 - 543. https://doi.org/10.1002/pds.5891
  • Mills, Mackenzie, Kanavos, Panos, Michaeli, Daniel, Miracolo, Aurelio (2024). Additional file 1 of Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. [Dataset]. figshare. https://doi.org/10.6084/m9.figshare.26568085
  • Politopoulou, Konstantina, Mills, Mackenzie, Kanavos, Panos (2023). HTA255 First-in-class drugs in HTA blunder or bliss? Value in Health, 26(12), S369 - S369. https://doi.org/10.1016/j.jval.2023.09.1938
    • LSE Health
  • Federico, Augustovski, Chávez, Danitza, Haig, Madeleine, Main, Caitlin, Argento, Fernando, Colaci, Carla, Mills, Mackenzie, Alfie, Verónica, Pichon Riviere, Andrés & Alcaraz, Andrea et al (2025). A Delphi study on valuing DNA sequencing in oncology: a European stakeholder developed framework for assessing next generation sequencing and comprehensive genomic profiling diagnostics. EBioMedicine, 121, https://doi.org/10.1016/j.ebiom.2025.105947 picture_as_pdf
  • Civitelli, Diego, Mills, Mackenzie, Kanavos, Panos (2025). HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28(6, Supplement 1), S259. https://doi.org/10.1016/j.jval.2025.04.1080
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843
  • Candore, Gianmario, Martin, Claire, Gabarro, Montse Soriano, Mills, Mackenzie, Kanavos, Panos, Bromley, Susan, Cooper, Amy L., Wolf, Birgit, Bolot, Paul & Franklin, Joe et al (2024). Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs: evidence from North America, Europe, and Australia. Pharmacoepidemiology and Drug Safety, 33, 542 - 543. https://doi.org/10.1002/pds.5891
  • Kanavos, Panos, Alcaraz, OA, Chávez, Danitza, Colaci, C, Haig, Madeleine, Argento, F, Main, Caitlin, Alfie, Verónica, Mills, Mackenzie & Pichon-Riviere, DA et al (2023). HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe: building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Value in Health, 26(12), S355 - S355. https://doi.org/10.1016/j.jval.2023.09.1870
    • Medical Technology Research Group (MTRG)
  • Civitelli, D., Politopoulou, K., Mills, Mackenzie, Kanavos, P. (2024). HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27(12, Supplement), S356 - S356. https://doi.org/10.1016/j.jval.2024.10.1843